

FIXED-DOSE VERSUS WEIGHT-BASED DOSING REGIMEN OF PEMBROLIZUMAB

A. Luaces-Rodríguez¹, P. Feijoo-Vilanova¹, L. Caeiro-Martínez¹, E. Gómez-Costa¹, A. Martínez-Pradedá¹, S. Rotea-Salvo¹, M. Domínguez-Guerra¹, T. Calleja-Chuclá¹, F. Busto-Fernández¹, I. Martín-Herranz¹.


¹Pharmacy Department, A Coruña University Hospital Complex, A Coruña (Spain)

4CPS-171
L01- ANTINEOPLASTIC AGENTS



andrea.luaces.rodriguez@sergas.es

BACKGROUND AND IMPORTANCE




Pembrolizumab is a PD-1 antibody, which was first approved with a dosage regimen of 2 mg/kg every 3 weeks. In 2018, marketing authorisation was changed to fixed dosing of 200 mg every 3 weeks.

The Commission of Pharmacy and Therapeutics of our region has taken the stance that based on the available evidence both regimens may be used.

Weight-based regimen


2 mg/kg/3 weeks



< 100 kg

Fixed-dose regimen


200 mg/3 weeks



≥ 100 kg

AIM AND OBJECTIVES

Evaluation of the **accordance to the protocol** established in our hospital for the dose of Pembrolizumab and to calculate the **financial impact** of this implementation.



MATERIAL AND METHODS



Naïve patients



1 year

Retrospective observational study



1081.75€

Variables analysed

Epidemiological

Weight

Cancer type


Initial dose

Protocol used

Change of the protocol

Data was extracted from our prescription software for chemotherapy (Oncofarm®).

RESULTS



CONCLUSION AND RELEVANCE

Although it was accorded to use weight-based strategy for the patients < 100 kg, the reality was that **less than 26% of the new pembrolizumab treatments** were in compliance with it.

However, it is true that approximately 10% of the patients were changed to the weight-based regimen in order to decrease the economical cost.

REFERENCES AND ACKNOWLEDGEMENTS

Keytruda : EPAR - Product information